[1] Gao W, Lei Y, Guo X, et al. Comparison and subsets analysis of peripheral CD4+ T cells in patients with psoriasis and psoriatic arthritis[J]. Mol Immunol, 2023, 163:174-180. [2] Penkava F, Velasco-Herrera M D C, Young M D, et al. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8+ T cells expressing tissue-homing receptors in psoriatic arthritis[J]. Nat Commun, 2020,11(1):4767. [3] Ogdie A, Grewal S K, Noe M H, et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study[J]. J Invest Dermatol, 2018, 138(4): 760-767. [4] Torosian K, Lal E, Kavanaugh A, et al. Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review[J]. Semin Arthritis Rheum, 2023, 59:152165. [5] Song L N, Liu J Y, Shi T T, et al. Angiotensin-(1-7), the product of ACE2 ameliorates NAFLD by acting through its receptor mas to regulate hepatic mitochondrial function and glycolipid metabolism[J]. FASEB J, 2020;34(12):16291-16306. [6] Chen C, Zhang C, Wang X, et al. Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome[J]. Eur J Gastroen Hepat, 2020, 32(7): 857. [7] Li B, Su R, Yan H, et al. Immunological risk factors for nonalcoholic fatty liver disease in patients with psoriatic arthritis: new predictive nomograms and natural killer cells[J]. Front Immunol, 2022, 13:907729. [8] 程功, 苏茵. 生物与靶向合成改善病情抗风湿药治疗PA的地位及进展[J]. 中华内科杂志, 2021, 60(5): 487-491. [9] Singh J A, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis[J]. Arthritis Care Res (Hoboken), 2019, 71(1): 2-29. [10] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. NAFLD诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 18(3): 163-166. [11] Jiao B, Wang B, Liu B, et al. Potential impact of ezetimibe on patients with NAFLD/NASH: a meta-analysis of randomized controlled trials[J]. Front Endocrinol (Lausanne), 2024, 15:1468476. [12] Cheng Y F, Chen M, Li X Y, et al. Exploring suicidal and self-injurious behaviors (SSIBs) signal strength of biologics in treating psoriasis or psoriatic arthritis: a 10-year real-world pharmacovigilance analysis using FAERS database[J]. J Am Acad Dermatol, S0190-9622(24)02992-X. [13] Zhong X, Huang D, Chen R, et al. Positive association between insulin resistance and fatty liver disease in psoriasis: evidence from a cross-sectional study[J]. Front Immunol, 2024, 15:1388967. [14] Costache D O, Blejan H, Cojocaru D L, et al. Intersecting pathways: nonalcoholic fatty liver disease and psoriasis duet-A comprehensive review[J]. Int J Mol Sci, 2024, 25(5):2660. [15] Hu J, Shao Y, Gui C, et al. Prevalence and risk of nonalcoholic fatty liver disease among adult psoriatic patients: a systematic review, meta-analysis, and trial sequential analysis[J]. Medicine (Baltimore), 2024, 103(18):e38007. [16] Li H, Su J, Zhu M, et al. Association between psoriasis and non-alcoholic fatty liver disease: a two-sample mendelian randomization study[J]. Clin Cosmet Investig Dermatol, 2023, 16:3291-3294. [17] Chularojanamontri L, Panjapakkul W, Paringkarn T, et al. The steatosis-associated fibrosis estimator (SAFE) score for assessing significant liver fibrosis in patients with psoriasis[J]. Clin Exp Dermatol, 2024, 49(4):337-343. [18] Ismail A M A, Saad A E, Draz R S. Effect of low-calorie diet on psoriasis severity index, triglycerides, liver enzymes, and quality of life in psoriatic patients with non-alcoholic fatty liver disease. Reumatologia, 2023, 61(2):116-122. [19] Panjiyar R, Mahajan R, Bhatia A, et al. Cross-sectional study to estimate the prevalence and risk factors of nonalcoholic fatty liver disease in children and adolescents with psoriasis[J]. Clin Exp Dermatol, 2023, 48(1):12-19. |